Yao Yu1, Javier Villanueva-Meyer2, Matthew R Grimmer3, Stephanie Hilz3, David A Solomon4, Serah Choi5, Michael Wahl6, Tali Mazor7, Chibo Hong3, Anny Shai3, Joanna J Phillips3,4, Bruce H Wainer8, Michael McDermott3,9, Daphne Haas-Kogan10, Jennie W Taylor3,11, Nicholas Butowski3, Jennifer L Clarke3,11, Mitchel S Berger3, Annette M Molinaro3, Susan M Chang3, Joseph F Costello3, Nancy Ann Oberheim Bush3,11. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 2. Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA. 3. Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA. 4. Division of Neuropathology, Department of Pathology, University of California, San Francisco, San Francisco, California, USA. 5. Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. 6. Department of Radiation Oncology, St. Charles Cancer Center, Bend, Oregon, USA. 7. Department of Computational Biology, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA. 8. Franklin County Coroner, Columbus, Ohio, USA. 9. Department of Neurosurgery, Baptist Health South Florida, Florida, USA. 10. Department of Radiation Oncology, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA. 11. Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Abstract
BACKGROUND: Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation. We aimed to determine the prevalence of TMZ-induced hypermutation at recurrence and prognostic implications. METHODS: We sequenced recurrent tumors from 82 patients with initially low-grade IDH-mutant gliomas who underwent reoperation and correlated hypermutation status with grade at recurrence and subsequent clinical outcomes. RESULTS: Hypermutation was associated with high-grade disease at the time of reoperation (OR 12.0 95% CI 2.5-115.5, P = .002) and was identified at transformation in 57% of recurrent LGGs previously exposed to TMZ. After anaplastic (grade III) transformation, hypermutation was associated with shorter survival on univariate and multivariate analysis (HR 3.4, 95% CI 1.2-9.9, P = .024), controlling for tumor grade, subtype, age, and prior radiotherapy. The effect of hypermutation on survival after transformation was validated in an independent, published dataset. Hypermutated (HM) tumors were more likely to develop discontiguous foci of disease in the brain and spine (P = .003). To estimate the overall incidence of high-grade transformation among low-grade IDH-mutant tumors, data from a phase II trial of TMZ for LGG were analyzed. Eight-year transformation-free survival was 53.8% (95% CI 42.8-69.2), and 61% of analyzed transformed cases were HM. CONCLUSIONS: TMZ-induced hypermutation is a common event in transformed LGG previously treated with TMZ and is associated with worse prognosis and development of discontiguous disease after recurrence. These findings impact tumor classification at recurrence, prognostication, and clinical trial design.
BACKGROUND: Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors with TMZ-induced hypermutation. We aimed to determine the prevalence of TMZ-induced hypermutation at recurrence and prognostic implications. METHODS: We sequenced recurrent tumors from 82 patients with initially low-grade IDH-mutant gliomas who underwent reoperation and correlated hypermutation status with grade at recurrence and subsequent clinical outcomes. RESULTS: Hypermutation was associated with high-grade disease at the time of reoperation (OR 12.0 95% CI 2.5-115.5, P = .002) and was identified at transformation in 57% of recurrent LGGs previously exposed to TMZ. After anaplastic (grade III) transformation, hypermutation was associated with shorter survival on univariate and multivariate analysis (HR 3.4, 95% CI 1.2-9.9, P = .024), controlling for tumor grade, subtype, age, and prior radiotherapy. The effect of hypermutation on survival after transformation was validated in an independent, published dataset. Hypermutated (HM) tumors were more likely to develop discontiguous foci of disease in the brain and spine (P = .003). To estimate the overall incidence of high-grade transformation among low-grade IDH-mutant tumors, data from a phase II trial of TMZ for LGG were analyzed. Eight-year transformation-free survival was 53.8% (95% CI 42.8-69.2), and 61% of analyzed transformed cases were HM. CONCLUSIONS: TMZ-induced hypermutation is a common event in transformed LGG previously treated with TMZ and is associated with worse prognosis and development of discontiguous disease after recurrence. These findings impact tumor classification at recurrence, prognostication, and clinical trial design.
Authors: Radhika Mathur; Yalan Zhang; Matthew R Grimmer; Chibo Hong; Michael Zhang; Saumya Bollam; Kevin Petrecca; Jennifer Clarke; Mitchel S Berger; Joanna J Phillips; Nancy Ann Oberheim-Bush; Annette M Molinaro; Susan M Chang; Joseph F Costello Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello Journal: Science Date: 2013-12-12 Impact factor: 47.728
Authors: Cassie N Kline; Nancy M Joseph; James P Grenert; Jessica van Ziffle; Eric Talevich; Courtney Onodera; Mariam Aboian; Soonmee Cha; David R Raleigh; Steve Braunstein; Joseph Torkildson; David Samuel; Michelle Bloomer; Alejandra G de Alba Campomanes; Anuradha Banerjee; Nicholas Butowski; Corey Raffel; Tarik Tihan; Andrew W Bollen; Joanna J Phillips; W Michael Korn; Iwei Yeh; Boris C Bastian; Nalin Gupta; Sabine Mueller; Arie Perry; Theodore Nicolaides; David A Solomon Journal: Neuro Oncol Date: 2017-05-01 Impact factor: 12.300
Authors: Philip Jonsson; Andrew L Lin; Robert J Young; Natalie M DiStefano; David M Hyman; Bob T Li; Michael F Berger; Ahmet Zehir; Marc Ladanyi; David B Solit; Angela G Arnold; Zsofia K Stadler; Diana Mandelker; Michael E Goldberg; Juliann Chmielecki; Maryam Pourmaleki; Shahiba Q Ogilvie; Shweta S Chavan; Andrew T McKeown; Malbora Manne; Allison Hyde; Kathryn Beal; T Jonathan Yang; Craig P Nolan; Elena Pentsova; Antonio Omuro; Igor T Gavrilovic; Thomas J Kaley; Eli L Diamond; Jacqueline B Stone; Christian Grommes; Adrienne Boire; Mariza Daras; Anna F Piotrowski; Alexandra M Miller; Philip H Gutin; Timothy A Chan; Viviane S Tabar; Cameron W Brennan; Marc Rosenblum; Lisa M DeAngelis; Ingo K Mellinghoff; Barry S Taylor Journal: Clin Cancer Res Date: 2019-07-01 Impact factor: 12.531
Authors: Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300
Authors: Hanwen Bai; Akdes Serin Harmancı; E Zeynep Erson-Omay; Jie Li; Süleyman Coşkun; Matthias Simon; Boris Krischek; Koray Özduman; S Bülent Omay; Eric A Sorensen; Şevin Turcan; Mehmet Bakırcığlu; Geneive Carrión-Grant; Phillip B Murray; Victoria E Clark; A Gulhan Ercan-Sencicek; James Knight; Leman Sencar; Selin Altınok; Leon D Kaulen; Burcu Gülez; Marco Timmer; Johannes Schramm; Ketu Mishra-Gorur; Octavian Henegariu; Jennifer Moliterno; Angeliki Louvi; Timothy A Chan; Stacey L Tannheimer; M Necmettin Pamir; Alexander O Vortmeyer; Kaya Bilguvar; Katsuhito Yasuno; Murat Günel Journal: Nat Genet Date: 2015-11-30 Impact factor: 38.330
Authors: Erica H Bell; Peixin Zhang; Edward G Shaw; Jan C Buckner; Geoffrey R Barger; Dennis E Bullard; Minesh P Mehta; Mark R Gilbert; Paul D Brown; Keith J Stelzer; Joseph P McElroy; Jessica L Fleming; Cynthia D Timmers; Aline P Becker; Andrea L Salavaggione; Ziyan Liu; Kenneth Aldape; David G Brachman; Stanley Z Gertler; Albert D Murtha; Christopher J Schultz; David Johnson; Nadia N Laack; Grant K Hunter; Ian R Crocker; Minhee Won; Arnab Chakravarti Journal: J Clin Oncol Date: 2020-07-24 Impact factor: 50.717
Authors: Brigitta G Baumert; Monika E Hegi; Martin J van den Bent; Andreas von Deimling; Thierry Gorlia; Khê Hoang-Xuan; Alba A Brandes; Guy Kantor; Martin J B Taphoorn; Mohamed Ben Hassel; Christian Hartmann; Gail Ryan; David Capper; Johan M Kros; Sebastian Kurscheid; Wolfgang Wick; Roelien Enting; Michele Reni; Brian Thiessen; Frederic Dhermain; Jacoline E Bromberg; Loic Feuvret; Jaap C Reijneveld; Olivier Chinot; Johanna M M Gijtenbeek; John P Rossiter; Nicolas Dif; Carmen Balana; Jose Bravo-Marques; Paul M Clement; Christine Marosi; Tzahala Tzuk-Shina; Robert A Nordal; Jeremy Rees; Denis Lacombe; Warren P Mason; Roger Stupp Journal: Lancet Oncol Date: 2016-09-27 Impact factor: 54.433
Authors: Kingson Lin; Susan E Gueble; Ranjini K Sundaram; Eric D Huseman; Ranjit S Bindra; Seth B Herzon Journal: Science Date: 2022-07-28 Impact factor: 63.714
Authors: Antonio Dono; Kristin Alfaro-Munoz; Yuanqing Yan; Carlos A Lopez-Garcia; Zaid Soomro; Garret Williford; Takeshi Takayasu; Lindsay Robell; Nazanin K Majd; John de Groot; Yoshua Esquenazi; Carlos Kamiya-Matsuoka; Leomar Y Ballester Journal: Neurosurgery Date: 2022-05-01 Impact factor: 5.315
Authors: Timothy E Richardson; Mariano S Viapiano; James F Lyon; Varshini Vasudevaraja; Kanish Mirchia; Jamie M Walker; Robert J Corona; Lawrence S Chin; Ivy Tran; Matija Snuderl Journal: Acta Neuropathol Commun Date: 2021-06-30 Impact factor: 7.801